Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...

Rising costs in pharmaceutical expenditure have become a major concern for policy makers in Germany over the last years. Therefore the pharmaceutical market in Germany has been increasingly targeted by different kinds of regulations, focussing both on the supply and the demand side, using price,...

This paper discusses the influence of recent health care reform acts in Germany on choice, guidance and access from the perspective of patients, insured, insurers, and health care providers. Particular emphasis is put on health policy reforms since 2004, i.e. the Social Health Insurance...

Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...

We try to better understand possible reasons for deviations between statistically-measured competitive balance (CB) and perceived CB. Moreover, we suggest answers to the following questions: are there specific dimensions of CB that are perceived to be significantly less balanced in the Danish...

Klappentext: In diesem Band wurden Beiträge von Autoren zusammengestellt, die Prof. Dr. Udo Müller im Laufe seines wissenschaftlichen Werdeganges begleitet haben. Entsprechend der großen Bandbreite seiner Interessen und Tätigkeitsbereiche in Forschung und Lehre umfasst dieses Buch ein...